|  | H3K27me3 expression (%) |  | |
---|---|---|---|---|
Variables | Case | low | high | P |
Age (years) | Â | Â | Â | 0.255 |
   ≤55a | 54 | 32(59.3) | 22(40.7) |  |
   >55 | 44 | 21(47.7) | 23(52.3) |  |
Gender | Â | Â | Â | 0.720 |
   Male | 82 | 45(54.9) | 37(45.1) |  |
   Female | 16 | 8(50.0) | 8(50.0) |  |
Location | Â | Â | Â | 0.341 |
   Cervical | 24 | 15(62.5) | 9(37.5) |  |
   Thoracic | 74 | 38(51.4) | 36(48.6) |  |
WHO grade | Â | Â | Â | 0.016 |
   G1 | 24 | 16(66.7) | 8(33.3) |  |
   G2 | 50 | 30(60.0) | 20(40.0) |  |
   G3-4 | 24 | 7(29.2) | 17(70.8) |  |
Tumor size (cm) | Â | Â | Â | 0.019 |
   ≤6b | 56 | 36(64.3) | 20(35.7) |  |
   >6 | 42 | 17(40.5) | 25(59.5) |  |
T status | Â | Â | Â | 0.024 |
   T2-3 | 47 | 31(66.0) | 16(34.0) |  |
   T4 | 51 | 22(43.1) | 29(56.9) |  |
N status | Â | Â | Â | 0.929 |
   N0 | 16 | 8(50.0) | 8(50.0) |  |
   N1 | 82 | 40(48.8) | 42(51.2) |  |
M status | Â | Â | Â | 0.651 |
   M0 | 59 | 33(55.9) | 26(44.1) |  |
   M1-lymc | 39 | 20(51.3) | 19(48.7) |  |
CRT response | Â | Â | Â | 0.094 |
   Effective | 61 | 37(60.7) | 24(39.3) |  |
   Resistant | 37 | 16(43.2) | 21(56.8) |  |
Locoregional progression | Â | Â | Â | 0.009 |
   Absent | 51 | 34(66.7) | 17(33.3) |  |
   Present | 47 | 19(40.4) | 28(59.6) |  |
Distant progression | Â | Â | Â | 0.299 |
   Absent | 62 | 36(58.1) | 26(41.9) |  |
   Present | 36 | 17(47.2) | 19(52.8) |  |